Strategic Partnership Teva Canada recently entered a strategic partnership with Novartis Canada to relaunch Mayzent for SPMS in Canada, indicating openness to collaboration and potential co-sell or co-market opportunities across specialty therapies.

Leadership Update A new general manager was appointed in July 2024, signaling potential governance changes and strategic shifts that could favor new sales initiatives, channel realignment, and renewed focus on growth in both generics and specialty areas.

Specialty Focus Teva Canada sits within a global specialty portfolio strong in CNS disorders, respiratory diseases, oncology, and women's health, presenting cross-sell opportunities by pairing generic offerings with specialty treatments and device-enabled solutions.

Market Footprint With a long-standing Canadian presence since 1965 and a workforce of over a thousand, Teva Canada has established distribution channels and relationships that can be leveraged to expand product uptake, including launches of innovative inhalers and autoinjectors.

Customer Engagement Initiatives like Life Effects and patient-support programs indicate a focus on patient outcomes and engagement, which can be translated into value-based selling approaches, partnerships with clinics, and payer discussions to drive adoption.